Skip to main content
Fig. 4 | Journal of Nanobiotechnology

Fig. 4

From: Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19

Fig. 4

Three types of nanovesicles effectively neutralized the spike-pseudotyped virus. a 293 T and 293 T-ACE2 cells infected with the packaged spike-pseudotyped virus at different MOIs. Scale bar: 200 nm. b Serial twofold dilution of the three types of nanovesicles were co-incubated with the spike pseudoviruses (wild type, WT) for 10 min, and then the mixture was added to 293 T-ACE2 cells. After 36 h, the IC50 of the three types of nanovesicles was detected by measuring the luciferase expression levels in 293 T-ACE2 cells. c The IC50 of CR3022 Exos, B38 Exos and CR3022/B38 Exos was detected by measuring the luciferase expression levels in 293 T-ACE2 cells. d CR3022/B38 and ACE2 NVs are used in combination to neutralize the spike pseudoviruses (WT). e The IC50 of neutralization of the spike pseudoviruses (N439K mutant) by CR3022 NVs, B38 NVs, and CR3022/B38 NVs

Back to article page